基本信息
浏览量:22
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
Born in Santiago de Compostela (Spain), on its University he graduated and obtained his pH.D. in Biological Sciences (1990) studying the cellular and molecular biology of thymosins, thymus-derived proteins. As a postdoctoral researcher at the NIH (Bethesda, MD, USA), he worked for almost six years in Dr. Westphal’s Group (NICHD, NIH). There, he became familiar with different transgenesis methodologies in mice (Cre/loxP system, knock out technology and conditional mouse mutants), applied to study the role of oncogenes (SV40 largeT), tumor suppressor (p53) and growth factors (GDNF) genes in oncogenesis and embryonic development. Some of these models and mice are still being profusely used as tools for in vivo genetic modification (e.g. the EIIa-Cre transgenic mouse line, published in PNAS, 1996) and the GDNF knock out mouse had and still has a great scientific impact as a model for kidney development, neurogenegesis and spermatogenesis (published in Nature, 1996, and Science, 2000) alterations. In 1996 he returned to the Center for Biological Research (CIB /CSIC, Madrid), where he started investigating the role of insulin-like growth factors (IGFs) in lung development using mutant mice. In 1999, as a FIS (ISCIII) Researcher at the Hospital of Mérida (Badajoz, Spain) he launched a Laboratory in Molecular Biology (Research Unit) to investigate in cancer. In 2002, he moved to the CIC (Centro de Investigación del Cáncer USAL-CSIC, Salamanca (Spain), as a CSIC Ramón y Cajal Researcher (first call), where he led a small independent research group on mechanisms of action of growth factors in lung development and lung cancer (published in Lung Cancer) collaborating with the local Hospital. In 2006 he was accredited as an I3 researcher (Spain).
Since 2009, Dr. García Pichel is the PI of the Lung Cancer and Respiratory Diseases Group at the CIBIR (FRS, Logroño), where he investigates the implication of IGF genes in pulmonary pathologies. The main interest of his Group is to investigate the implication of proteins of the IGFs system (Insulin-like Growth Factors) in homeostasis and pathologies of the respiratory system. Specifically, their possible clinical utility is explored either as biomarkers that facilitate, speed up and improve early diagnoses and prognoses, or as molecular targets for the design of new treatments, where the main IGF receptor protein (IGF1R or Insulin-like Growth Factor 1 Receptor) appears as a therapeutic target of great interest. To carry out this research, the Group uses in vitro cell cultures, and pharmacological or genetically modified animal models (such as IGF1R-deficient mice). His Group has generated several animal models to study IGFs function in the respiratory system and other organs homeostasis, field in which they are pioneers. These models have been revealed as powerful research tools to understand the implication of IGF1R signaling in respiratory diseases such as acute lung injury, asthma, COPD and lung cancer, as demonstrate the Group’s recent publications and collaborations. In 2019 joined the CIBERES Group # CB06/06/0009 (ISCIII, Spanish Gob.) as a Research Collaborator. His Group collaborates with clinicians at the Logroño’s Hospital, to access to access patients, and also with pioneer national and international Groups, including: Prof. Isabel Varela, (IIBm; CSIC, Madrid) on IGFs and inner ear pathologies; Dr. Andreas Höflich (FBN; Dummerstof, Germany) on IGFBPs; Dr. Mikael Adner (Karolinska Institutet; Stockholm) on asthma models; Dr. G. Peces-Barba (Fundación Jiménez Díaz, Madrid) on COPD, Prof. J-M. Senard (Pharmacologie, Toulouse, France), Dr. Pedro Baptista (IIB Zaragoza) on hepatic regeneration, Prof. Martin Wizenrath (Charity Hospital, Univ. Berlin) on pneumonies, and Dr. Mª Calzada (Hosp. La Princesa, Madrid) on lung injury. Since 2014, his Group also successfully collaborates with chemists at La Rioja Univ. (MATMO Group) to investigate nanoteranostic applications of newly synthesized photoemissive organometallic compounds and nanoparticles, as anticancer agents and biomarkers for respiratory diseases.
He has participated in COST Action BM1201, UE (2014-2016) (Management Committee), was member of the La Rioja and Salamanca Univ. Animal Bioethical Committees (OEBA), and he is an evaluator of national (AEI/MICINN, Spain), and international Projects. Accredited as Associate Lecturer, he teaches in the Chemistry and Biotechnology Master, and trains postgrad students (Univ. La Rioja). He has directed 6 doctoral theses, and 3 ongoing. Scientific Societies member: SEBBM (FEBS), of which he is the Treasury, and also of the SEPAR/ERS. Active disseminator of his research in mass media and social networks.
Bibliometrics: 48 publications. Publons: h index, 24; 44 public., 6 as first author, 16 as last author; 4,478 citations, 121 cites/year; 142 co-authors. Google Scholar: 62 publi., i10 index, 36; 6,123 citations. Res. Gate: score, 2,363; 5,110 citations, h: 24.
研究兴趣
论文共 66 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
EMBO Reportsno. 8 (2023)
EMBO reportsno. 8 (2023)
Dalton Transactionsno. 35 (2023): 12390-12403
Molecular pathology and functional genomics (2022)
J. Garcia Pichel,I. Lopez, S. Pineiro-Hermida, M. Canalejo, C. M. Gotera Rivera, J. Sola, A. Roncero Lazaro, G. Peces-Barba, C. Ruiz-Martinez,E. Alfaro-Arnedo
Biomedicinesno. 4 (2022): 733-733
Mechanisms of lung injury and repair (2022)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn